Cardiovascular Systems Inc (CSII) Position Increased by Partner Investment Management L.P.
Partner Investment Management L.P. boosted its holdings in shares of Cardiovascular Systems Inc (NASDAQ:CSII) by 31.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,329 shares of the medical device company’s stock after purchasing an additional 2,695 shares during the quarter. Partner Investment Management L.P.’s holdings in Cardiovascular Systems were worth $366,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the stock. Champlain Investment Partners LLC raised its stake in Cardiovascular Systems by 15.0% during the 1st quarter. Champlain Investment Partners LLC now owns 2,590,330 shares of the medical device company’s stock valued at $56,806,000 after purchasing an additional 336,975 shares during the period. BlackRock Inc. raised its stake in Cardiovascular Systems by 9.3% during the 2nd quarter. BlackRock Inc. now owns 2,479,543 shares of the medical device company’s stock valued at $80,188,000 after purchasing an additional 210,128 shares during the period. Cortina Asset Management LLC raised its stake in Cardiovascular Systems by 8.6% during the 1st quarter. Cortina Asset Management LLC now owns 841,013 shares of the medical device company’s stock valued at $18,443,000 after purchasing an additional 66,768 shares during the period. FMR LLC raised its stake in Cardiovascular Systems by 187.0% during the 2nd quarter. FMR LLC now owns 516,100 shares of the medical device company’s stock valued at $16,690,000 after purchasing an additional 336,300 shares during the period. Finally, First Light Asset Management LLC raised its stake in Cardiovascular Systems by 3.7% during the 2nd quarter. First Light Asset Management LLC now owns 487,207 shares of the medical device company’s stock valued at $15,756,000 after purchasing an additional 17,520 shares during the period. 84.56% of the stock is currently owned by institutional investors.
CSII has been the topic of several recent analyst reports. BidaskClub downgraded Cardiovascular Systems from a “buy” rating to a “hold” rating in a research note on Wednesday, August 1st. Bank of America raised Cardiovascular Systems from an “underperform” rating to a “buy” rating in a research note on Wednesday, June 27th. Stifel Nicolaus began coverage on Cardiovascular Systems in a report on Wednesday, August 22nd. They set a “buy” rating and a $45.00 price target for the company. Zacks Investment Research cut Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. Finally, Lake Street Capital restated a “buy” rating and set a $50.00 price target on shares of Cardiovascular Systems in a report on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $35.20.
Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings results on Monday, July 30th. The medical device company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05. The business had revenue of $59.15 million during the quarter, compared to analysts’ expectations of $58.43 million. Cardiovascular Systems had a return on equity of 1.36% and a net margin of 0.79%. research analysts forecast that Cardiovascular Systems Inc will post -0.07 EPS for the current fiscal year.
In other Cardiovascular Systems news, CFO Jeffrey S. Points sold 971 shares of the firm’s stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $37.54, for a total transaction of $36,451.34. Following the completion of the transaction, the chief financial officer now owns 23,229 shares in the company, valued at approximately $872,016.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Scott R. Ward purchased 2,500 shares of the business’s stock in a transaction on Wednesday, August 29th. The shares were purchased at an average price of $38.39 per share, with a total value of $95,975.00. Following the acquisition, the chief executive officer now directly owns 278,362 shares in the company, valued at $10,686,317.18. The disclosure for this purchase can be found here. Insiders have sold a total of 3,177 shares of company stock valued at $119,274 in the last 90 days. 3.30% of the stock is currently owned by company insiders.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Featured Article: Understanding Analyst Recommendations
Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems Inc (NASDAQ:CSII).
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.